Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Disc Medicine ( (IRON) ).
On October 3, 2025, Mona Ashiya, Ph.D., a member of the Board of Directors at Disc Medicine, Inc., resigned from her position, including her roles on the Compensation Committee and the Nominating and Corporate Governance Committee. Her resignation was not due to any disagreements with the company, and following her departure, the Board’s size was reduced from nine to eight members.
The most recent analyst rating on (IRON) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
Spark’s Take on IRON Stock
According to Spark, TipRanks’ AI Analyst, IRON is a Neutral.
Disc Medicine’s stock score reflects the challenges faced by biotechnology firms in early stages, with significant cash burn and negative earnings. However, a strong cash position and low leverage provide some financial stability. Technical indicators suggest mixed signals with short-term consolidation but potential longer-term weakness. Valuation metrics indicate current unprofitability, a common trait for growth-focused biotech companies.
To see Spark’s full report on IRON stock, click here.
More about Disc Medicine
Average Trading Volume: 342,061
Technical Sentiment Signal: Buy
Current Market Cap: $2.36B
Learn more about IRON stock on TipRanks’ Stock Analysis page.